{"nctId":"NCT01651949","briefTitle":"Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003)","startDateStruct":{"date":"2012-10-29","type":"ACTUAL"},"conditions":["Genital Warts","Anal Cancer","Anal Intraepithelial Neoplasia"],"count":2520,"armGroups":[{"label":"Females","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: 9vHPV Vaccine"]},{"label":"Heterosexual Males","type":"EXPERIMENTAL","interventionNames":["Biological: 9vHPV Vaccine"]},{"label":"Men who have Sex with Men","type":"EXPERIMENTAL","interventionNames":["Biological: 9vHPV Vaccine"]}],"interventions":[{"name":"9vHPV Vaccine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Good physical health\n* Has never had Papanicolaou testing (Pap, cervical or anal) or has only had normal Pap test results\n* Other inclusion criteria will be discussed with the investigator\n\nExclusion Criteria:\n\n* History of severe allergic reaction that required medical intervention\n* Currently enrolled in a clinical trial\n* If participant is female, pregnant\n* Currently immunocompromised or having received immunosuppressive therapy in the last year\n* Positive test for HPV\n* History of HPV-related external genital lesions or HPV-related anal lesions or anal cancer\n* If participant is female, history of abnormal cervical biopsy results\n* Other exclusion criteria will be discussed with the investigator","healthyVolunteers":true,"sex":"ALL","minimumAge":"16 Years","maximumAge":"26 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Geometric Mean Titers (GMTs) to the HPV Types Contained in the 9vHPV Vaccine","description":"Serum antibodies to HPV types 6/11/16/18/31/33/45/52/58 were measured with a Competitive Luminex Immunoassay. Titers are reported in milli Merck Units/mL","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"782.0","spread":null},{"groupId":"OG001","value":"703.9","spread":null},{"groupId":"OG002","value":"568.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"616.7","spread":null},{"groupId":"OG001","value":"564.9","spread":null},{"groupId":"OG002","value":"437.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3346.0","spread":null},{"groupId":"OG001","value":"2788.3","spread":null},{"groupId":"OG002","value":"2294.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"808.2","spread":null},{"groupId":"OG001","value":"679.8","spread":null},{"groupId":"OG002","value":"608.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"708.5","spread":null},{"groupId":"OG001","value":"570.1","spread":null},{"groupId":"OG002","value":"420.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"384.8","spread":null},{"groupId":"OG001","value":"322.0","spread":null},{"groupId":"OG002","value":"252.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"235.6","spread":null},{"groupId":"OG001","value":"185.7","spread":null},{"groupId":"OG002","value":"157.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"386.8","spread":null},{"groupId":"OG001","value":"335.2","spread":null},{"groupId":"OG002","value":"233.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"509.8","spread":null},{"groupId":"OG001","value":"409.3","spread":null},{"groupId":"OG002","value":"319.8","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With One or More Injection-site Adverse Experiences Prompted on the Vaccination Report Card","description":"An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE. Injection-site AEs prompted on the Vaccination Report Card (VRC) were erythema, pain, and swelling. Participants were instructed to use the Vaccination Report Card to record AEs daily after each study vaccination.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7","spread":null},{"groupId":"OG001","value":"84.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.7","spread":null},{"groupId":"OG001","value":"32.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.4","spread":null},{"groupId":"OG001","value":"82.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.2","spread":null},{"groupId":"OG001","value":"37.5","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Elevated Oral Body Temperature (>=37.8° C, >=100° F)","description":"Participants were instructed by the investigator to use the Vaccination Report Card to document evening oral temperature daily after each study vaccination","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":null},{"groupId":"OG001","value":"5.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Seroconversion to the HPV Types Contained in the 9vHPV Vaccine","description":"Serum antibodies to HPV types were measured with a Competitive Luminex Immunoassay. The serostatus cutoffs (milli Merck U/mL) for HPV types were as follows: HPV Type 6: ≥30; HPV Type 11: ≥16; HPV Type 16: ≥20; HPV Type 18: ≥24; HPV Type 31: ≥10; HPV Types 33, 45, 52, and 58: ≥8.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.6","spread":null},{"groupId":"OG001","value":"99.6","spread":null},{"groupId":"OG002","value":"99.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"99.9","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"99.9","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.9","spread":null},{"groupId":"OG001","value":"99.8","spread":null},{"groupId":"OG002","value":"99.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"99.9","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.8","spread":null},{"groupId":"OG001","value":"99.5","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"99.8","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"99.8","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With an Adverse Event","description":"An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76.2","spread":null},{"groupId":"OG001","value":"89.4","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Had Study Vaccine Discontinued Due to an Adverse Event","description":"An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study vaccine, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study vaccine is also an AE.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":null},{"groupId":"OG001","value":"0.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":23,"n":1394},"commonTop":["Injection site pain","Injection site swelling","Injection site erythema","Headache"]}}}